Palifosfamide
Palifosfamide is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
363 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcoma | D012509 | — | — | 15 | 44 | 24 | 1 | 8 | 84 |
| Large b-cell lymphoma diffuse | D016403 | — | C83.3 | 11 | 17 | 3 | 1 | — | 28 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 16 | 2 | 1 | 1 | 21 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 2 | 4 | 9 | 4 | — | 17 |
| Germ cell and embryonal neoplasms | D009373 | — | — | 1 | 12 | 2 | 1 | 1 | 16 |
| Burkitt lymphoma | D002051 | — | C83.7 | 1 | 5 | — | 2 | — | 7 |
| Large-cell lymphoma anaplastic | D017728 | — | C84.6 | 3 | 4 | — | 1 | — | 6 |
| T-cell lymphoma peripheral | D016411 | — | — | 3 | 1 | — | 1 | — | 4 |
| Enteropathy-associated t-cell lymphoma | D058527 | — | C86.2 | 1 | — | — | 1 | — | 2 |
| Mediastinal neoplasms | D008479 | — | C38.3 | — | — | 1 | 1 | — | 2 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 9 | 36 | 7 | — | 3 | 49 |
| Neoplasms | D009369 | — | C80 | 17 | 8 | 3 | — | 1 | 24 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 7 | 13 | 5 | — | — | 19 |
| Osteosarcoma | D012516 | — | — | 5 | 9 | 4 | — | 3 | 18 |
| Leukemia | D007938 | — | C95 | 2 | 10 | 6 | — | 1 | 18 |
| Hodgkin disease | D006689 | — | C81 | 8 | 12 | 2 | — | — | 16 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 3 | 6 | 3 | — | 1 | 12 |
| Central nervous system neoplasms | D016543 | — | — | 4 | 8 | 2 | — | — | 11 |
| Ewing sarcoma | D012512 | EFO_0000173 | — | 1 | 3 | 1 | — | 4 | 9 |
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 1 | 4 | 5 | — | — | 9 |
Show 34 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 8 | — | — | — | 8 |
| B-cell lymphoma | D016393 | — | — | 3 | 3 | — | — | — | 5 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | 5 | — | — | — | 5 |
| Mantle-cell lymphoma | D020522 | — | C83.1 | 3 | 3 | — | — | — | 4 |
| Follicular lymphoma | D008224 | — | C82 | 2 | 4 | — | — | — | 4 |
| Testicular neoplasms | D013736 | — | C62 | 1 | 2 | — | — | — | 3 |
| Embryonal carcinoma | D018236 | — | — | — | 2 | — | — | — | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | 1 | — | — | 1 | 2 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 2 | 1 | — | — | — | 2 |
| T-cell lymphoma | D016399 | — | — | 2 | 1 | — | — | — | 2 |
Show 30 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Primitive neuroectodermal tumors | D018242 | — | — | 1 | — | — | — | 2 | 3 |
| Retinoblastoma | D012175 | — | — | 1 | — | — | — | 1 | 2 |
| Mycosis fungoides | D009182 | — | C84.0 | 1 | — | — | — | — | 1 |
| Thymoma | D013945 | — | — | 1 | — | — | — | — | 1 |
| T-cell leukemia | D015458 | — | — | 1 | — | — | — | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | — | — | 2 | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 1 | 1 |
| Nausea | D009325 | HP_0002018 | R11.0 | — | — | — | — | 1 | 1 |
| Medulloblastoma | D008527 | — | — | — | — | — | — | 1 | 1 |
| Hepatoblastoma | D018197 | — | C22.2 | — | — | — | — | 1 | 1 |
| Retinal neoplasms | D019572 | — | C69.2 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Palifosfamide |
| INN | palifosfamide |
| Description | Isophosphamide mustard is a phosphorodiamide. |
| Classification | Small molecule |
| Drug class | phosphoro-derivatives; isophosphoramide mustard derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=P(O)(NCCCl)NCCCl |
Identifiers
| PDB | — |
| CAS-ID | 31645-39-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL889 |
| ChEBI ID | 80566 |
| PubChem CID | 100427 |
| DrugBank | — |
| UNII ID | 6A4U6NN813 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 155 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use